Phase 1 US: 50 μg MSP142/AS01 (N = 54 # ) n(%) | ||||
 | G1 | G2 | G3 | Any |
Pain | 27 (50%) | 17 (31%) | 6 (11%) | 50 (93%) |
Redness | 7 (13%) | 5 (9%) | 11 (20%) | 23 (43%) |
Swelling | 4 (7%) | 7 (13%) | 24 (44%) | 35 (65%) |
Fever | 7 (13%) | 10 (19%) | 3 (6%) | 20 (37%) |
Fatigue | 18 (33%) | 14 (26%) | 6 (11%) | 38 (70%) |
Nausea | 2 (4%) | 2 (4%) | 1 (2%) | 5 (9%) |
Headache | 8 (15%) | 15 (28%) | 5 (9%) | 28 (52%) |
Malaise | 11 (20%) | 12 (22%) | 7 (13%) | 30 (56%) |
Myalgias | 11 (20%) | 9 (17%) | 6 (11%) | 26 (48%) |
Joint Pain | 9 (17%) | 8 (15%) | 3 (6%) | 20 (37%) |
Phase 1 Kenya: 50 μg MSP142/AS01 (N = 59 # ) n(%) | ||||
 | G1 | G2 | G3 | Any |
Pain | 36 (61%) | 17 (29%) | 0 (0%) | 53 (90%) |
Redness | 4 (7%) | 0 (0%) | 1 (2%) | 5 (8%) |
Swelling | 10 (17%) | 0 (0%) | 1 (2%) | 11 (19%) |
Fever | 2 (3%) | 0 (0%) | 0 (0%) | 2 (3%) |
Fatigue | 5 (8%) | 4 (7%) | 0 (0%) | 9 (15%) |
Nausea | 3 (5%) | 1 (2%) | 0 (0%) | 4 (7%) |
Headache | 15 (25%) | 6 (10%) | 1 (2%) | 22 (37%) |
Malaise | 5 (8%) | 5 (8%) | 0 (0%) | 10 (17%) |
Myalgias | 3 (5%) | 2 (3%) | 0 (0%) | 5 (8%) |
Joint Pain | 4 (7%) | 3 (5%) | 0 (0%) | 7 (12%) |